ArticlePloS one2014
Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Stromal-based proteome data improve stratification of hormone receptor-positive breast cancer.NPJ breast cancer · 2026Article
- Low tumoral Trefoil Factor 1 expression relates to aggressive tumor features and poor survival in young women with breast cancer.Scientific reports · 2026Article
- Reduced GATA3 expression associates with immuno-metabolic alterations and aggressive features in breast cancer.The journal of pathology. Clinical research · 2025Article
- Article
- Predicting estrogen receptor status from HE-stained breast cancer slides using artificial intelligence.Frontiers in medicine · 2025Article
- VEGFA gene variants are associated with breast cancer progression.The journal of pathology. Clinical research · 2024Article
- AI improves accuracy, agreement and efficiency of pathologists for Ki67 assessments in breast cancer.Scientific reports · 2024Article
- Vessel size as a marker of survival in estrogen receptor positive breast cancer.Breast cancer research and treatment · 2023Article
- Hypoxia induced responses are reflected in the stromal proteome of breast cancer.Nature communications · 2023Article
- Associations of alcohol consumption with breast tissue composition.Breast cancer research : BCR · 2023Article
- Article
- Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.The journal of pathology. Clinical research · 2021Article
- Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.Breast cancer research and treatment · 2021Article
- Effect of neoadjuvant therapy on breast cancer biomarker profile.BMC cancer · 2020Article
- Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.Breast cancer research and treatment · 2020Article
- Integrin α11β1 is expressed in breast cancer stroma and associates with aggressive tumor phenotypes.The journal of pathology. Clinical research · 2020Article
- Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.Breast cancer research and treatment · 2019Article
- Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort.Scientific reports · 2019Article
- A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients.Cancer science · 2019Article
- Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.BMC cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTumor cell proliferation in breast cancer is strongly prognostic and may also predict response to chemotherapy. However, there is no consensus on counting areas or cut-off values for patient stratification. Our aim was to assess the matched level of proliferation by Ki67 when using different tissue categories (whole sections, WS; core needle biopsies, CNB; tissue microarrays, TMA), and the corresponding prognostic value.
methodsWe examined a retrospective, population-based series of breast cancer (n = 534) from the Norwegian Breast Cancer Screening Program. The percentage of Ki67 positive nuclei was evaluated by visual counting on WS (n = 534), CNB (n = 154) and TMA (n = 459).
resultsThe median percentage of Ki67 expression was 18% on WS (hot-spot areas), 13% on CNB, and 7% on TMA, and this difference was statistically significant in paired cases. Increased Ki67 expression by all evaluation methods was associated with aggressive tumor features (large tumor diameter, high histologic grade, ER negativity) and reduced patient survival.
conclusionThere is a significant difference in tumor cell proliferation by Ki67 across different sample categories. Ki67 is prognostic over a wide range of cut-off points and for different sample types, although Ki67 results derived from TMA sections are lower compared with those obtained using specimens from a clinical setting. Our findings indicate that specimen specific cut-off values should be applied for practical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.